Skip to main content

An official website of the United States government

U.S. Department of Health & Human Services

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


FOR IMMEDIATE RELEASE

Thursday, December 4, 2025​

Contact ASPR Press Office
ASPRMedia@hhs.gov
aspr.hhs.gov/newsroom
X: @ASPRgov


HHS Provides Doses of Investigational Vaccine, Therapeutic to Ethiopia to Address Current Outbreak of Marburg Virus 





The Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) announces the provision of up to 2,500 doses of Sabin Vaccine Institute’s investigational cAd3-Marburg Vaccine and up to 25 treatment courses of Mapp Biopharmaceutical’s investigational MBP091 monoclonal antibody therapeutic to Ethiopia to support the country’s response to its first-ever outbreak of Marburg virus disease.

“While case numbers remain limited, HHS is taking the Marburg virus outbreak seriously, and we are acting early,” HHS Deputy Secretary and Acting Director of the Centers for Disease Control and Prevention (CDC) Jim O’Neill said. “Together with CDC and ASPR, HHS will end this threat swiftly.”

Marburg is a highly contagious hemorrhagic fever disease and can have a case fatality rate up to 90 percent if patients are not properly managed. As of December 2, 2025, the Ethiopian Ministry of Health has confirmed 13 cases of Marburg, including eight deaths.

“Providing these products demonstrates the U.S. government’s longstanding commitment to life-saving humanitarian aid, keeping Americans safe at home and abroad, and the Trump Administration’s transition towards efficient and country-led assistance,” said Principal Deputy Assistant Secretary for ASPR John Knox. “This action will protect U.S. national security and the health of Americans.”

Both investigational products are under development by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and are being made available through contracts with their respective manufacturers. Both products will be administered under appropriate regulatory mechanisms to ensure that any safety concerns are identified through proper oversight. These products are being made available to potentially protect and treat health care and front-line workers in Ethiopia.


# # #